9 unknown, 6 completed, 3 recruiting, 2 suspended. 13 Phase 1, 12 Phase 2, 1 Phase 3.
Follow vorolanib: new trials by email Literature Review of vorolanib trials Research Report on vorolanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants vorolanib and rifampicin, vorolanib and itraconazole - DDI (Drug-Drug Interaction) | Phase 1 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 36 | 2026-09-01 | 2026-09-09 |
| Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment vorolanib, Vorolanib - Hepatic Impairment (HI) | Phase 1 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 36 | 2026-09-01 | 2026-09-09 |
| Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC Pucotenlimab combination with Vorolanib - Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 2 | Recruiting | Sun Yat-sen University | 21 | 2025-07-10 | 2026-02-04 |
| Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma Vorolanib Tablets, Vorolanib + Toripalimab - Renal Cell Carcinoma (RCC), Adjuvant | Phase 2 | Active not recruiting | Dong Wen | 60 | 2025-04-24 | 2025-07-09 |
| Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients Vorolanib, cadonilimab - Kidney Cancer, RCC | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 37 | 2024-08-31 | 2024-08-29 |
| Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy Vorolanib Tablets, Sintilimab Injection - Renal Cell Carcinoma, Immunotherapy | Phase 2 | Unknown | Hao Zeng | 67 | 2024-08-01 | 2024-07-26 |
| Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph - Diabetic Macular Edema | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 27 | 2024-01-15 | 2025-03-04 |
| Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) EYP-1901, Sham IVT - Nonproliferative Diabetic Retinopathy | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 77 | 2022-09-28 | 2025-08-15 |
| Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Vorolanib, Atezolizumab - Extensive-stage Small Cell Lung Cancer | Phase 2 | Terminated | Washington University School of Medicine | 11 | 2020-10-07 | 2025-11-03 |
| Bioequivalency Study of CM082 Tablet in Healthy Volunteers CM082 tablet (test product), CM082 tablet (reference product) - Advanced Malignant Solid Tumors | Phase 1 | Completed | AnewPharma | 96 | 2020-06-01 | 2021-11-26 |
| A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers CM082 with fed or fasting - Advanced Malignant Solid Tumors | Phase 1 | Completed | AnewPharma | 24 | 2019-12-19 | 2020-05-21 |
| CM082 in Patients With Myopic Choroidal Neovascularization (CNV) CM082 - Myopic Choroidal Neovascularisation | Phase 1 | Suspended | AnewPharma | 96 | 2019-12-18 | 2021-03-10 |
| CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) CM082 plus JS001 - Small Cell Lung Cancer | Phase 2 | Unknown | AnewPharma | 30 | 2019-09-18 | 2020-07-09 |
| CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). CM082 plus JS001 - Non-small Cell Lung Cancer | Phase 2 | Unknown | AnewPharma | 20 | 2019-04-02 | 2020-07-09 |
| Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors CM082 - Advanced Malignant Solid Tumors | Phase 1 | Unknown | AnewPharma | 19 | 2019-02-26 | 2022-11-14 |
| Safety and Tolerability of Oral CM082 in Patients With wAMD CM082 - Age-Related Macular Degeneration | Phase 2 | Unknown | AnewPharma | 64 | 2018-11-22 | 2020-01-13 |
| Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors Vorolanib, Nivolumab, Pembrolizumab - Solid Tumor, Hepatocellular Carcinoma | Phase 1 | Terminated | Washington University School of Medicine | 16 | 2018-09-11 | 2020-07-29 |
| Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. CM082 plus JS001 - Mucosal Melanoma | Phase 2 | Unknown | AnewPharma | 40 | 2018-07-31 | 2019-07-05 |
| Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Vorolanib, Nivolumab - Thymic Carcinoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 88 | 2018-07-10 | 2024-10-08 |
| Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer CM082 plus paclitaxel - Advanced Gastric Cancer | Phase 1 | Unknown | AnewPharma | 21 | 2018-03-15 | 2019-02-21 |
Showing 20 of 24. Sign in to see all of them.
Carcinoma, Renal Cell (4) · Small Cell Lung Carcinoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Macular Degeneration (2) · Carcinoma, Hepatocellular (1) · Kidney Neoplasms (1) · Stomach Neoplasms (1) · Thymoma (1)
AnewPharma (13) · Betta Pharmaceuticals Co., Ltd. (2) · EyePoint Pharmaceuticals, Inc. (2) · Washington University School of Medicine (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Dong Wen (1) · Hao Zeng (1) · Sun Yat-sen University (1) · Vanderbilt-Ingram Cancer Center (1)
China (18) · United States (5)
Jun Guo, M.D (2) · Aiping Zhou, MD (1) · Daniel Morgensztern, MD (1) · Hao Zeng, Doctor (1) · Jin Li, M.D (1) · Jin-Wan Wang, M.D. (1) · Jun Guo, MD (1) · Kathryn Beckermann, MD (1) · Ming Zhang, MD (1) · Nusayba A Bagegni, M.D. (1) · Ramiro Ribeiro, MD (1) · Ramiro Ribeiro, MD, PhD (1) · Xinan Sheng, M.D (1) · Yin Shen (1)